Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes

被引:4
|
作者
Tan, Jinlin [1 ]
Wu, Zhilong [2 ]
Hu, Peipei [3 ]
Gan, Lin [4 ]
Wang, Ying [1 ]
Zhang, Dingmei [1 ,5 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Peoples R China
[2] Fourth Peoples Hosp Foshan City, Foshan 528000, Peoples R China
[3] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[4] Huangpu Dist Ctr Dis Control & Prevent, Guangzhou 510700, Peoples R China
[5] NMPA Key Lab Qual Monitoring & Evaluat Vaccines &, Guangzhou 510080, Peoples R China
来源
PATHOGENS | 2022年 / 11卷 / 09期
关键词
SARS-CoV-2; PLpro; COVID-19; mutation; outcome; INSIGHTS;
D O I
10.3390/pathogens11091008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papain-like protease (PLpro) is important for the replication and transcription of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to reveal the PLpro mutations associated with the clinical outcomes of patients. Due to the importance of the S protein in the pathogenicity of SARS-CoV-2, the mutation of the S protein was also analyzed in this study. After downloading the data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database, samples were divided into two groups on the basis of patient status, namely, recovered and dead groups. This study performed a univariate analysis and further explored the association of mutations with patient outcomes through multivariate logistic regression analysis. A total of 138,492 samples were used for analysis. The patients had a mean age of 43.66 +/- 21.56 years, and 51.3% of them were female. Multivariate logistic regression results showed that, compared with men, women had a lower risk of dying from coronavirus disease 2019 (COVID-19) (OR = 0.687, 95%CI: 0.638-0.740). Compared with patients aged 17 years and younger, patients aged 18-64 years (OR = 2.864, 95%CI: 1.982-4.139) and patients over 65 years old (OR = 19.135, 95%CI: 13.280-27.572) had a higher risk of death after infection. Compared with the wild type, P78L (OR = 5.185, 95%CI: 2.763-9.730) and K233Q (OR = 5.154, 95%CI: 1.442-18.416) in PLpro were associated with an increased risk of death. A synergistic interaction existed between age and mutations A146D and P78L. The results of the multivariate logistic regression analysis of the data on vaccinated patients demonstrated that, compared with the wild type, the P78L (OR = 3.376, 95%CI: 2.040-5.585) mutation was associated with an increased risk of death. In conclusion, compared with the wild-type PLpro protein, the P78L and K233Q mutations may increase the risk of death in infected individuals. In addition, a synergistic effect existed between age and P78L and K233Q that increased the risk of death in older patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (Mpro) and Papain-like Protease (PLpro)
    Omage, Folorunsho Bright
    Madabeni, Andrea
    Tucci, Amanda Resende
    Nogara, Pablo Andrei
    Bortoli, Marco
    Rosa, Alice dos Santos
    Ferreira, Vivian Neuza dos Santos
    Rocha, Joao Batista Teixeira
    Miranda, Milene Dias
    Orian, Laura
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 63 (07) : 2226 - 2239
  • [22] Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery
    Amin, Sk. Abdul
    Ghosh, Kalyan
    Singh, Samayaditya
    Qureshi, Insaf Ahmed
    Jha, Tarun
    Gayen, Shovanlal
    MOLECULAR DIVERSITY, 2022, 26 (01) : 215 - 228
  • [23] Targeting SARS-CoV-2 papain-like protease in the postvaccine era
    Ton, Anh-Tien
    Pandey, Mohit
    Smith, Jason R.
    Ban, Fuqiang
    Fernandez, Michael
    Cherkasov, Artem
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (11) : 906 - 919
  • [24] Review of the crystallized structures of the SARS-CoV-2 papain-like protease
    Qiu, Yue
    Jiang, Hua-Juan
    Yang, Yu-Shun
    Hu, Xiao-Qin
    Zeng, Xue-Wen
    JOURNAL OF MOLECULAR STRUCTURE, 2025, 1333
  • [25] SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads
    Ghosh, Arun K.
    Shahabi, Dana
    Imhoff, Mackenzie E. C.
    Kovela, Satish
    Sharma, Ashish
    Hattori, Shin-ichiro
    Higashi-Kuwata, Nobuyo
    Mitsuya, Hiroaki
    Mesecar, Andrew D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 96
  • [26] Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro
    Kiba, Yuka
    Tanikawa, Takashi
    Kitamura, Masashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (05) : 965 - 966
  • [27] Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
    Ma, Chunlong
    Wang, Jun
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (02) : 102 - 109
  • [28] SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition
    Ullrich, Sven
    Nitsche, Christoph
    CHEMBIOCHEM, 2022, 23 (19)
  • [29] Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
    Tan, Haozhou
    Hu, Yanmei
    Jadhav, Prakash
    Tan, Bin
    Wang, Jun
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (11) : 7561 - 7580
  • [30] Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity
    Velma, Ganga Reddy
    Shen, Zhengnan
    Holberg, Cameron
    Fu, Jiqiang
    Soleymani, Farinaz
    Cooper, Laura
    Ramos, Omar Lozano
    Indukuri, Divakar
    Musku, Soumya Reddy
    Rychetsky, Pavel
    Slilaty, Steve
    Li, Zuomei
    Ratia, Kiira
    Rong, Lijun
    Schenten, Dominik
    Xiong, Rui
    Thatcher, Gregory R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (16) : 13681 - 13702